Nature Communications (Feb 2024)

Proteomic characterization identifies clinically relevant subgroups of soft tissue sarcoma

  • Shaoshuai Tang,
  • Yunzhi Wang,
  • Rongkui Luo,
  • Rundong Fang,
  • Yufeng Liu,
  • Hang Xiang,
  • Peng Ran,
  • Yexin Tong,
  • Mingjun Sun,
  • Subei Tan,
  • Wen Huang,
  • Jie Huang,
  • Jiacheng Lv,
  • Ning Xu,
  • Zhenmei Yao,
  • Qiao Zhang,
  • Ziyan Xu,
  • Xuetong Yue,
  • Zixiang Yu,
  • Sujie Akesu,
  • Yuqin Ding,
  • Chen Xu,
  • Weiqi Lu,
  • Yuhong Zhou,
  • Yingyong Hou,
  • Chen Ding

DOI
https://doi.org/10.1038/s41467-024-45306-y
Journal volume & issue
Vol. 15, no. 1
pp. 1 – 24

Abstract

Read online

Abstract Soft tissue sarcoma is a broad family of mesenchymal malignancies exhibiting remarkable histological diversity. We portray the proteomic landscape of 272 soft tissue sarcomas representing 12 major subtypes. Hierarchical classification finds the similarity of proteomic features between angiosarcoma and epithelial sarcoma, and elevated expression of SHC1 in AS and ES is correlated with poor prognosis. Moreover, proteomic clustering classifies patients of soft tissue sarcoma into 3 proteomic clusters with diverse driven pathways and clinical outcomes. In the proteomic cluster featured with the high cell proliferation rate, APEX1 and NPM1 are found to promote cell proliferation and drive the progression of cancer cells. The classification based on immune signatures defines three immune subtypes with distinctive tumor microenvironments. Further analysis illustrates the potential association between immune evasion markers (PD-L1 and CD80) and tumor metastasis in soft tissue sarcoma. Overall, this analysis uncovers sarcoma-type-specific changes in proteins, providing insights about relationships of soft tissue sarcoma.